SynthesisClinical and experimental medicine2023
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study.
Synthesis in Clinical and experimental medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
113 citing papers in PubMed, 2 syntheses or guidelines pooled it, 158 citations in OpenAlex.
- Pooled it
- Preoperative glasgow prognostic score was an effective prognostic indicator in patients with biliary tract cancer.Frontiers in immunology · 2025Pooled it
- A Telemedicine App for Nonrigid Facial Rehabilitation Training Enhanced by Efficient Fully Convolutional Neural Network With Residual Network (EffiFCNN-ResNet) to Improve Accessibility for Patients With Nasopharyngeal Carcinoma Cancer: Randomized Controlled Trial.JMIR mHealth and uHealth · 2026Trial
- Trial
- Overall survival following palliative immune checkpoint inhibitor treatment according to ECOG performance status: a large registry-based study.Acta oncologica (Stockholm, Sweden) · 2026Article
- Real-World 30-Day Mortality After the Last Dose of Immune Checkpoint Inhibitors: A Multicenter Retrospective Cohort Study in Turkey.Current oncology (Toronto, Ont.) · 2026Article
- Clinical, Dermatoscopic, Histological and Molecular Prognostic and Predictive Factors of Metastatic Melanoma Response to Immunotherapy: A Systematic Review and Drug Class Meta-Analysis.Journal of clinical medicine · 2026Review
- PD-1 inhibitor treatment outcomes for cutaneous squamous cell carcinoma in patients over 85: a comparative analysis.The oncologist · 2026Article
- Construction and validation of a prognostic nomogram for advanced esophageal squamous cell carcinoma patients treated with PD-1 inhibitor-based therapy.Discover oncology · 2026Article
- Genetic association of miR-146a, miR-196a2, and miR-499 polymorphisms with hepatocellular carcinoma risk in an Eastern Chinese population.Frontiers in oncology · 2026Article
- Outcomes and Safety of PD-1 Blockades Plus Anlotinib Regimen in Previously-Treated Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective, Exploratory Study.Drug design, development and therapy · 2026Article
- Primary small cell neuroendocrine carcinoma of the urinary tract: a case report and literature review.World journal of surgical oncology · 2025Review
- Modeling unobserved heterogeneity in multistate event history data using frailty and weighted survival approaches.Scientific reports · 2025Article
- Real-world effectiveness of Avelumab maintenance in advanced urothelial carcinoma: results from the Italian multicenter MALVA study (Meet-URO 25).The oncologist · 2025Observational
- Neoadjuvant systemic therapy for hepatocellular carcinoma: challenges and opportunities-a narrative review.Hepatobiliary surgery and nutrition · 2025Review
- Prognostic factors affecting mortality in elderly, low body mass index, and poor performance status groups with lung cancer: analysis of the 2016 Korean Association of Lung Cancer Registry (KALC-R) database.Translational lung cancer research · 2025Article
- Assessing the risks and benefits of investigational new drugs in adult phase-I oncology trials in China, 2013-2021.Investigational new drugs · 2025Review
- Predictive and Prognostic Significance of Patient-Reported Outcomes for Survival and Adverse Events in Daratumumab-Treated Multiple Myeloma.European journal of haematology · 2025Article
- Preoperative ECOG performance status as a predictor of outcomes in upper tract urothelial cancer surgery.Scientific reports · 2025Article
- Efficacy of microwave ablation for intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.Quantitative imaging in medicine and surgery · 2025Article
53 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ECOG performance status (PS) is a pivotal prognostic factor in a wide number of solid tumors. We performed a meta-analysis to assess the role of ECOG PS in terms of survival in patients with ECOG PS 0 or ECOG PS 1 treated with immunotherapy alone or combined with other anticancer treatments. Following the Preferred Reporting Items for Systematic Reviews and Meta-analyses, all phase II and III randomized clinical trials that compared immunotherapy or immune-based combinations in patients with solid tumors were retrieved. The outcomes of interest were overall survival (OS) and progression-free survival (PFS). We also performed subgroup analyses focused on type of therapy (ICI monotherapy or combinations), primary tumor type, setting (first line of treatment, subsequent lines). Overall, 60 studies were included in the analysis for a total of 35.020 patients. The pooled results showed that immunotherapy, either alone or in combination, reduces the risk of death or progression in both ECOG PS 0 and 1 populations. The survival benefit was consistent in all subgroups. Immune checkpoint inhibitors monotherapy or immune-based combinations are associated with improved survival irrespective of ECOG PS 0 or 1. Clinical trials should include more frail patients to assess the value of immunotherapy in these patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.